The top targets, EGFR, CASP3, SRC, TNF, MMP9, STAT3, and ERBB2, were selected as the core targets for molecular docking with the core compound of HQHG for ITP treatment. Here, ERBB2 is linked to autoimmune thrombocytopenic purpura.